Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$797.45 USD

797.45
4,442,440

+21.07 (2.71%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $798.95 +1.50 (0.19%) 7:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata

The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.

Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat

Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.

Eli Lilly (LLY) Increases Despite Market Slip: Here's What You Need to Know

In the latest trading session, Eli Lilly (LLY) closed at $792.28, marking a +1.3% move from the previous day.

The Zacks Analyst Blog Highlights Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic

Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for Eli Lilly, Procter & Gamble & Morgan Stanley

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), The Procter & Gamble Company (PG) and Morgan Stanley (MS).

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Market Edge Highlights: AAPL, COST, WSM, LLY and HLT

AAPL, COST, WSM, LLY and HLT have been highlighted in this Market Edge article.

Tracey Ryniec headshot

How to Start Stock Investing in Your 50s

Think you're too old to start buying stocks? Think again. Here's some tips.

Sweta Killa headshot

5 Best-Performing S&P 500 Stocks Halfway Through Q1

Nvidia (NVDA), Eli Lilly (LLY), Meta Platforms (META), Uber Technologies (UBER) and Ralph Lauren (RL) are the five best-performing stocks in the S&P 500.

The Zacks Analyst Blog Highlights Mastercard, SAP, CrowdStrike, Eli Lilly and AMETEK

Mastercard, SAP, CrowdStrike, Eli Lilly and AMETEK are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Mastercard, SAP & CrowdStrike

Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), SAP SE (SAP) and CrowdStrike Holdings, Inc. (CRWD).

Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates

Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Sweta Killa headshot

A Look at Pharma ETFs After Q4 Earnings

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Kinjel Shah headshot

Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals

Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.

Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development

Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.

Zacks Market Edge Highlights: NVDA, LLY, CMG, DECK and VRT

NVDA, LLY, CMG, DECK and VRT have been highlighted in this Market Edge article.

Tracey Ryniec headshot

Should You Buy a Stock on its All-Time Highs?

There is a stock you love but it's red hot and has gone vertical. Do you dive in or wait for a sell-off?

Sweta Killa headshot

ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat

Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.

Amgen (AMGN) Q4 Earnings Top, Horizon Drugs Drive Sales

Amgen (AMGN) beats fourth-quarter estimates for earnings and sales. Horizon's products add $954 million in sales in the quarter.

Compared to Estimates, Lilly (LLY) Q4 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Earnings Data Deluge

Earnings Data Deluge.

Eli Lilly (LLY) Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales

Eli Lilly (LLY) beats fourth-quarter estimates for earnings as well as sales. The company issues an upbeat guidance for 2024.